- Loyola Law School (J.D., 2011), salutatorian, summa cum laude, Sayre Macneil Scholar, Order of the Coif, St. Thomas More Law Honor Society
- University of California, Santa Barbara (B.S., Biochemistry and Molecular Biology, 2007), with high honors
Irell In The News
Lauren Drake is an associate in the Los Angeles office of Irell & Manella LLP, where she is a member of the firm’s litigation and IP litigation practice groups. Ms. Drake's practice encompasses a wide-range of complex commercial litigation, with an emphasis on patent disputes. She has extensive experience representing clients in the pharmaceutical and biotechnology industries. Ms. Drake is admitted to practice before the U.S. Patent and Trademark Office.
Ms. Drake earned her J.D., summa cum laude, from Loyola Law School in 2011, where she was salutatorian of her class and Note & Comment Editor of the Loyola of Los Angeles Law Review. She earned her B.S., with high honors, in Biochemistry and Molecular Biology from the University of California, Santa Barbara in 2007.
Celltrion v. Genentech
Defending Genentech in connection with IPR petitions in the PTAB for multiple patents relating to methods of using Genentech’s blockbuster drug, rituximab.
PDL BioPharma v. Merck
Secured a $19.5-million lump-sum payment from Merck to settle PDL BioPharma’s lawsuit filed in the District of New Jersey alleging that Merck’s manufacture of its cancer drug Keytruda infringed a foundational patent relating to the humanization of recombinant antibodies. The case settled little more than one year after it was filed, following the claim construction hearing.
- Bio-Rad Laboratories et al. v. 10x Genomics
Currently representing 10x Genomics in a patent infringement suit filed in the District of Delaware relating to methods of preparing DNA samples for sequencing involving the use of microfluidic technology. Trial is scheduled for April 2018.
- NantKwest, Inc. v. Lee
Currently representing NantKwest before the district court and the Federal Circuit in a 35 U.S.C. section 145 action relating to natural killer cell-based therapies for cancer.
- Ariosa Diagnostics, Inc. v. Sequenom, Inc.
Represented Ariosa Diagnostics in patent litigation against Sequenom. Ariosa brought an early summary judgment motion, and on October 30, 2013, the court invalidated Sequenom’s patent because it attempted to cover a natural phenomenon, which is not patent-eligible. The decision gave Ariosa a complete victory, allowing the diagnostics company to continue selling its popular Harmony™ Prenatal Test – an affordable, highly accurate, non-invasive blood test to determine fetal chromosomal abnormalities. This decision was affirmed by the Federal Circuit in a precedential opinion.
- Verinata Health, Inc. v. Ariosa Diagnostics
Currently representing Ariosa Diagnostics in a patent infringement suit filed by Verinata which, like the action involving Sequenom, seeks to enjoin Ariosa from selling its innovative non-invasive test for fetal chromosomal abnormalities.
- PDL BioPharma, Inc. v. Genentech, Inc. (Arbitration)
Represented PDL BioPharma, which pioneered technology relating to humanization of recombinant antibodies, in a complex breach of contract matter. The matter settled on terms favorable to PDL.
- Regeneron Pharmaceuticals, Inc. v. Genentech, Inc.
Represented Regeneron Pharmaceuticals in connection with a patent case in the Southern District of New York relating to Regeneron’s Eylea and Zaltrap anti-angiogenesis drugs.
- "Preventing Inequity: Extending Issue Preclusion to Claim Construction During Reexamination of Previously Litigated Patents," Loyola Law Review
Bar & Court Admissions
- 2011, California
- U.S. District Court, Central and Northern Districts of California
- U.S. Court of Appeals, Federal Circuit
- U.S. Patent and Trademark Office